Shares of Geron Co. (NASDAQ:GERN) rose 5.2% during trading on Friday . The company traded as high as $2.06 and last traded at $2.04. Approximately 2,402,647 shares traded hands during mid-day trading, an increase of 72% from the average daily volume of 1,400,139 shares. The stock had previously closed at $1.94.
GERN has been the topic of a number of research reports. Needham & Company LLC reissued a “hold” rating on shares of Geron in a research note on Friday, November 3rd. Stifel Nicolaus reissued a “hold” rating and issued a $2.50 price objective on shares of Geron in a research note on Friday, November 3rd. Zacks Investment Research raised Geron from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a research note on Tuesday, October 3rd. Finally, BidaskClub raised Geron from a “strong sell” rating to a “sell” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $3.75.
Geron (NASDAQ:GERN) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.40 million. Geron had a negative return on equity of 25.14% and a negative net margin of 2,992.67%. Geron’s revenue for the quarter was down 96.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.02) earnings per share. sell-side analysts forecast that Geron Co. will post -0.17 EPS for the current fiscal year.
Geron Company Profile
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.